10-Q: Neuronetics Q2 Revenue Soars 132% Post-Greenbrook Deal

Neuronetics reported a significant revenue increase in Q2 2025, primarily driven by the Greenbrook acquisition, though net losses persisted and gross margins declined.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 132% to $38.1 million, and by 107% to $70.1 million for the six months ended June 30, 2025, primarily due to the acquisition of Greenbrook TMS Inc.
• The Greenbrook acquisition, completed December 9, 2024, contributed $23.0 million in clinic revenue for Q2 2025 and $41.7 million for the six months ended June 30, 2025.
• Net loss for the three months ended June 30, 2025, was $9.8 million, consistent with the prior year, but increased to $22.5 million for the six months ended June 30, 2025, up from $17.7 million in the prior year.
• Gross margin decreased significantly to 46.6% in Q2 2025 from 74.0% in Q2 2024, and to 47.8% from 74.6% for the six months ended June 30, 2025, primarily due to the inclusion of Greenbrook's clinic business and reduced treatment session revenue.
• The company completed a secondary public offering on February 10, 2025, raising net proceeds of $18.9 million.
• As of June 30, 2025, cash and cash equivalents stood at $11.0 million, with an accumulated deficit of $442.6 million.
• Negative cash flows from operating activities totaled $20.5 million for the six months ended June 30, 2025.

Sentiment

Score: 4

Explanation: While revenue growth is substantial due to the Greenbrook acquisition, the company continues to incur significant net losses, and gross margins have compressed. The ongoing need for capital raises (secondary offering, ATM program, additional debt) and persistent negative operating cash flow indicate continued financial challenges despite strategic expansion. The decrease in core system sales and treatment session revenue (excluding Greenbrook) is also a concern.

Positives

• Achieved substantial revenue growth of 132% in Q2 2025 and 107% for the six months ended June 30, 2025, primarily driven by the strategic acquisition of Greenbrook TMS Inc.
• Loss from operations improved slightly in Q2 2025, decreasing to $8.058 million from $8.507 million in Q2 2024.
• Research and development expenses decreased by 20% in Q2 and 26% year-to-date, reflecting personnel expense savings from post-acquisition restructuring.
• Successfully completed a secondary public offering on February 10, 2025, raising net proceeds of $18.9 million, strengthening capital resources.
• Management believes current cash and anticipated revenues are sufficient to fund operations for at least the next 12 months.
• The NeuroStar Advanced Therapy System holds FDA clearances for multiple indications, including MDD, OCD, anxious depression in adults, and MDD in adolescents, demonstrating broad applicability.

Negatives

• Gross margin significantly decreased to 46.6% in Q2 2025 from 74.0% in Q2 2024, and to 47.8% from 74.6% for the six months ended June 30, 2025, primarily due to the lower-margin clinic business from Greenbrook.
• Net loss for the six months ended June 30, 2025, worsened to $22.5 million from $17.7 million in the prior year, indicating continued unprofitability.
• Negative cash flows from operating activities persisted, totaling $20.5 million for the six months ended June 30, 2025, an increase from $17.0 million in the prior year.
• Accumulated deficit increased to $442.6 million as of June 30, 2025.
• U.S. NeuroStar Advanced Therapy System sales volume decreased to 41 systems in Q2 2025 (from 49 in Q2 2024) and to 72 systems for the six months ended June 30, 2025 (from 89 in prior year).
• U.S. treatment session revenue decreased by 8% in Q2 and 17% year-to-date, partly due to the absence of sales to Greenbrook post-acquisition.
• General and administrative expenses increased significantly by 98% in Q2 and 109% year-to-date, primarily due to the inclusion of Greenbrook's G&A expenses.

Risks

• Ability to achieve or sustain profitable operations due to a history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System to generate revenues.
• Availability of coverage and reimbursement from third-party payors for treatments using the company's products.
• Potential adverse effects from global macroeconomic impacts, including inflation and recessionary pressures, on business, results of operations, and financial results.
• Ability to successfully roll-out the Better Me Provider Program on the planned timeline.
• Ability to achieve cash flow breakeven in the third quarter of 2025.
• Subject to various audits from government agencies, including Medicaid and Medicare, which involve the potential recoupment of reimbursements received from these agencies.
• The impact of the recently enacted One Big Beautiful Bill Act on consolidated financial statements is currently being evaluated.

Future Outlook

Management anticipates operating losses will lessen in the near term due to revenue growth and ongoing cost efficiencies from the Greenbrook acquisition. Clinic revenue is expected to increase in 2025, while international revenues are projected to decrease as a percentage of total revenue. Sales and marketing expenses are expected to increase, while research and development expenses are anticipated to decrease in 2025 compared to 2024. The company aims to achieve cash flow breakeven in the third quarter of 2025.

Management Comments

• "Mental health is as important as physical health."
• "As a global leader in neuroscience, we are delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results."
• "NeuroStar Advanced Therapy System is safe, clinically effective, reproducible and precise and we believe is supported by the largest clinical data set of any competing TMS system."
• "We believe we are the market leader in TMS therapy based on over 209,215 global patients treated with over 7.6 million of our treatment sessions through June 30, 2025."
• "Management believes that the Company’s cash and cash equivalents as of June 30, 2025 and anticipated revenues from sales of our products and services are sufficient to fund the Company’s operations for at least the next 12 months from the issuance of these consolidated financial statements."

Industry Context

The company operates in the growing neurohealth disorders market, specifically focusing on non-invasive treatments like Transcranial Magnetic Stimulation (TMS) for conditions such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). The acquisition of Greenbrook TMS Inc. significantly expands its footprint in direct patient care through treatment centers, diversifying its revenue streams beyond system sales and treatment sessions. This move positions Neuronetics to capture a larger share of the mental healthcare services market, aligning with broader trends towards integrated care models and expanding access to advanced therapies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards based solely on this filing is not possible.

Management Changes

Corporate Governance

Legal Proceedings

• Subject to various claims and legal actions arising during the ordinary course of business, but management believes none are expected to have a material adverse effect.
• Subject to various audits from government agencies including Medicaid and Medicare, which involve potential recoupment of reimbursements; impact cannot be estimated.

Related Party Transactions

• The Promissory Note outstanding principal amount of $3.6 million with TMS Neurohealth Centers Inc. (a Greenbrook subsidiary) was settled and recorded as additional purchase consideration as part of the Greenbrook acquisition.

Stakeholder Impact

• Shareholders: Experience dilution from recent and potential future equity offerings; face continued operating losses and negative cash flows.
• Customers: Benefit from expanded treatment options and access to NeuroStar Advanced Therapy and SPRAVATO through the Greenbrook acquisition.
• Employees: Impacted by restructuring efforts post-acquisition, leading to R&D personnel expense savings; changes in key management roles.
• Creditors: Company has $60.0 million outstanding under the Perceptive Facility, with additional $10.0 million borrowed, secured by substantially all assets. Compliance with covenants is ongoing.

Next Steps

• Continue to integrate Greenbrook into the overall internal control over financial reporting process.
• Evaluate the impact of the One Big Beautiful Bill Act on consolidated financial statements.
• Potentially offer and sell up to $50.0 million in common stock through the ATM Program.
• Achieve cash flow breakeven in the third quarter of 2025.

Key Dates

Recommendation

While Neuronetics has achieved substantial revenue growth through the Greenbrook acquisition, the financial results show continued net losses and a significant decline in gross margins, indicating challenges in profitability and integration. The company's reliance on ongoing capital raises (secondary offering, ATM program, new debt tranche) and persistent negative operating cash flow suggest a need for further financial stabilization. For existing investors, holding the stock might be prudent to observe the realization of anticipated synergies and progress towards cash flow breakeven. However, new investors should approach with caution due to the high-risk profile associated with continued losses and capital dependency.

Keywords

Neuronetics, NeuroStar, TMS, Transcranial Magnetic Stimulation, Mental Health, Depression Treatment, OCD Treatment, Greenbrook TMS, SEC Filing, 10-Q, Medical Devices, Neuroscience, Healthcare Services